Abstract: The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M2 protein bearing viruses. These compounds are also useful as inhibitors of the replication factors of hepatitis virus type C (HVC). The invention also describes pharmaceutical compositions containing the compounds of the invention either alone or in combination admixed with a suitable and pharmaceutically acceptable carrier.

Abstract: A pharmaceutical composition for preventing or treating hepatitis C is provided, including oleanolic acid derivatives as an active ingredient and a pharmaceutically acceptable carrier. A method for preventing or treating hepatitis C in a subject in need thereof is also provided by administering the subject the pharmaceutical composition given above.

Abstract: Stabilized mixtures of pesticides are disclosed.

Abstract: The present invention relates to novel derivatives of epirubicin, pharmaceutical composition comprising these derivatives, and uses of epirubicin and its derivative for treating HCV.

Abstract: Disclosed are various embodiments of intra-oral taste modification devices, both erodible and non-erodible, and methods for using the devices, and methods and kits for making the devices, for controlling food intake by reducing the desire to eat highly sweetened foods and refined carbohydrates.

Abstract: Lipid compositions comprising nuts, seeds, oils, legumes, fruits, grains, and dairy useful in specified amounts as dietary supplements and diet plans designed around and including the aforementioned for the prophylaxis and treatment of numerous diseases are disclosed. The compositions include omega-6 and omega-3 fatty acids where the ratio of the omega-6 to the omega-3 fatty acids and their amounts are controlled based on one or more factors including age of the subject, sex of the subject, diet of the subject, the body weight of the subject, medical conditions of the subject, and climate of the subject's living area.

Abstract: A 13-deoxy anthracycline and a taxane can be administered to a patient simultaneously, separately, sequentially, or consecutively to produce a therapeutic anticancer effect with reduced toxicity and side effect profile, compared to the administration of equieffective amounts of either compound alone. A composition or preparation of a 13-deoxy anthracyclines and a taxane for producing a potent anticancer therapeutic effect is also provided.

Abstract: Extracts of radix platycodin are used to inhibit angiogenesis, particularly angiogenesis that is associated with disease conditions other than obesity or cancer.

Abstract: The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and either or both of HSP70 and HSP90. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction.

Abstract: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.

Abstract: The present invention pertains to novel uses of glycyrrhetinic acid (GA), glycyrrhizic acid (GLA) and related compounds for prevention and/or treatment of pulmonary fibrosis, in particular, irradiation-induced pulmonary fibrosis. Also embodied are therapeutic uses of prodrugs, metabolites, derivatives (e.g., acids, esters and ethers), and salts of glycyrrhetinic acid (GA) and glycyrrhizic acid (GLA). The present invention also provides for therapeutic or pharmaceutical compositions comprising a compound of the invention in a form that can be combined with a pharmaceutically acceptable carrier.

Abstract: Pharmaceutical composition containing a combination of a non steroidal anti inflammatory drug and a colchicoside derivative, the active ingredients being present in the free state or in the form of a salt.

Abstract: The invention relates to compositions comprising at least one xanthine compound, preferably further comprising at least one agent which acts on capillary circulation and/or at least one natural moisturizing agent, which can be used to treat, or to reduce and/or minimize the appearance of, defects such as dark circles, bags and/or puffiness around eyes.

Abstract: The invention relates to a composition for caring for human keratinous fibres comprising, in a physiologically acceptable medium: a) at least one compound chosen from arginines, their organic or inorganic acid salts and their derivatives; b) at least one compound of the formula (I) in which R1=H or —CH3; R2=H or —CH3; R3=—CH3, R1 and R2 not simultaneously being H, or else a Centella asiatica extract comprising a compound or a mixture of compounds of formula (I); and optionally c) at least one compound of formula (II) in which w+x+y+z has a mean value of 4.

Abstract: The present invention related to cosmetic compositions comprising oridonin and new cosmetic uses. Oridonin is used for fighting the signs of cutaneous aging and for slimming. A composition comprising a combination of oridonin and darutigenol or a derivative thereof, in particular darutoside, is disclosed together with the cosmetic use of such composition.

Abstract: The invention provides novel saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to the regulation of apoptosis and cytotoxicity of cells and exhibit potent anti-tumor effects against a variety of tumor cells.

Abstract: Provided herein are multimodal barrier materials useful for preventing adhesions in a subject, which may include a collagen, a collagen deposition inhibitor and/or a chitosan.

Abstract: The present invention relates to the use of an 11-?-HSD-type 1 and/or type 2 inhibitor for the manufacture of a pharmaceutical agent for the prevention and/or treatment of inflammation-induced and/or immune-mediated loss of bone and/or cartilage.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating Hepatitis C, comprising the roots extract of Platycodon grandiflorum and/or saponin components in Platycodon grandiflorum useful as an antiviral agent. The composition of the present invention has no harm to human and inhibits the proliferation of Hepatitis C virus, so that it can be effectively used as a preventive or therapeutic agent for Hepatitis C.

Abstract: The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation. The invention is of use in particular in human dermatology or in reconstructive surgery.

Abstract: The invention relates to [6)O-?-D-Glcp-(1?]n-6-O-?-D-Glcp-(1?-phenolic derivatives. These [6)O-?-D-Glcp-(1?]n-6-O-?-D-Glcp-(1?-phenolic derivatives of selected phenolics are new, have a solubility in water higher than that of their parent O-?-D-Glcp-(1?-phenolic derivatives and have useful applications in cosmetic, nutrition and pharmaceutical compositions, such as treating or preventing oxidative stress, a cancer, a cardiovascular disease, a bacterial infection, a viral infection, a fungal infection, a UV-induced erythema, an allergy, a metabolism disorder, diabetes, an obesity, a hormonal disorder, a bone disease, a pain, a brain disease, a mouth or teeth disease, an inflammatory or immune disorder.

Abstract: 4-(trifluoromethanesulfonyloxyphenyl)propionic acid derivatives and pharmaceutical composition containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, these metabolites are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.

Abstract: The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z(n) whrein n is 0 or 1 and when n is 1, Z is an amino-acid residue devoidof sulfydryl group, or is a polypeptide, Cys is the amino-acid residue for Cysteine, T is a molecule linked by a covalent bound to the S part of Cys, selected in a group comprising: agents for in vivo diagnosis, cytotoxic agents, prodrugs, or enzymes for the conversion of a prodrug to a drug, Y(m) wherein m is 0 or 1 and when m is 1, Y is a linker between T and Cys, said linker being either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into said cells.

Abstract: A saponin extract from Saponaria vaccaria and its use for stimulating apoptosis in cancer cells and treating cancer is described. The saponin extract may be isolated from Saponaria vaccaria seed. The saponin extract may comprise one or more than one triterpene saponin. The triterpene saponin may comprise a bisdesmosidic saponin having a molecular weight selected from the group consisting of molecular weight 1448, 1464, 1422, 1526, 1596 and 1688. Bisdesmosidic saponin of molecular weight 1448, 1464, 1422, 1526, 1596 and 1688 isolated from Saponaria vaccaria seed may be used to treat human cancer including prostate cancer, human breast cancer and colon cancer. Also disclosed is a method of isolating the saponin extract.

Abstract: Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample.

Abstract: The instant application is directed to bidesmosidic betulin and betulinic acid saponin derivatives of formula (I), and use thereof as antitumor agents. In particular, said compounds are effective in treating lung carcinomas, colorectal adenocarcinomas, breast adenocarcinomas, and prostate adenocarcinomas. Methods of synthesizing said compounds through selective glycosylation of the C-28 and C-3 position, and diagnostic methods for identifying tumours suitable for treatment by said compounds are also disclosed.

Abstract: The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment of a Type IV hypersensitivity reaction or symptoms of a Type IV hypersensitivity reaction, such as in contact dermatitis, atopic dermatitis, hypersensitivity pneumonitis, chronic transplant rejection, graft versus host disease, cell mediated autoimmune diseases, Hashimoto's thyroiditis, Sjogren's disease, adrenalitis, polymyositis, or pernicious anemia.

Abstract: The invention describes novel triterpenoid 2-deoxy glycosides of general formula I, wherein at least one of the substituents X1 and R2 contains a 2-deoxy glycosidic group, method of preparation thereof, their cytotoxic activity and a pharmaceutical formulation containing these compounds.

Abstract: It is described the use of propionyl L-carnitine for treating disturbances of the skin such as cellulite.

Abstract: The present invention is successful in providing caffeic acid derivatives namely eicosanyl caffeate and docosyl caffeate from Glycyrrhiza. Also, the present invention provides a composition comprising said bio actives and also provides a process to prepare the composition. Ultimately, the invention provides solution for the management of ulcer.

Abstract: The present invention relates to a flavonoid compound having an antiviral activity, more particularly to a flavonoid compound obtained by extracting Houttuynia cordata with methanol and separating/purifying with chromatography, a method for efficient extraction and purification of the same and an antiviral composition comprising the compound as an active ingredient.

Abstract: A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T is provided, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-T of the formula I to a patient in need thereof wherein R1 is H, —OH, C1-6 alkoxy, —NR5R6, or Sac 1; R2 is H, —OH, C1-6 alkoxy or Sac 2; R3 is H, —OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties, and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof.

Abstract: The invention provides saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to the regulation of apoptosis and cytotoxicity of cells and exhibit potent anti-tumor effects against a variety of tumor cells.

Abstract: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Abstract: The present invention relates to application of compounds of formula (1) (Gibberellins) and their derivatives for the preparation of a pharmaceutical composition or medicaments for the treatment of diabetes, its complications and associated conditions, including obesity, micro and macro vascular diseases, nephropathy, neuropathy, eye diseases, diabetic ulcerations and the like. The method results the normalization of serum glucose level and other physiological conditions.

Abstract: The present invention provides compositions of avicins and avicin mixtures that enhance topical, percutaneous, transmucosal, transepithelial, transendothelial or transdermal transport of agents including diagnostic molecules, therapeutic drugs and cosmetic materials.

Abstract: The present invention relates to a process for preparing an extract from ivy leaves which includes the active ingredient hederacoside C and ?-hederin, and to extracts prepared by this process. According to this there is initially provision of a first, ?-hederin-rich extract and subsequently provision of a second, hederacoside C-rich extract. In a last step, the two extracts are blended to give an extract which has an adjusted hederacoside C content and an adjusted ?-hederin content.

Abstract: Described herein are progenitor cancer cells and cell lines isolated from human breast ductal carcinoma in situ (DCIS) lesions and the uses of these cells or cell lines in drug design, drug screening, and monitoring in vivo therapy. The DCIS malignant precursor cells or cell lines are epithelial in origin, are positive for markers of autophagy, show at least one genetic difference from normal cells of said fragment, form 3-D tube-like structures or ball aggregates, or are inhibited in formation of 3-D structures and migration by treatment with chloroquine. In one embodiment, there is a loss of heterozygosity (LOH) that is narrowly confined to a region of chromosome 6p (6p21.1-6p12.3) that contains the SUPT3H gene.

Abstract: The present invention relates to a cosmetic composition comprising: a) from about 0.05% to about 10% of a salt form active; b) from about 0.001% to about 2% of a thickening agent; and c) water, wherein the composition has a turbidity no higher than about 10 NTU, and has a pH in the range of about 5.0 to about 6.8.

Abstract: Extracts of Hoodia plant containing steroidal glycosides which have improved flavor, by virtue of reduced levels of discovered negative flavor compounds. Food compositions containing steroidal glycosides with reduced amounts of discovered negative flavor components are also included.

Abstract: A topical pharmaceutical gel includes flurbiprofen or a pharmaceutically acceptable salt of flurbiprofen, thiocolchicoside or a pharmaceutically acceptable salt of thiocolchicoside, and menthol. Pharmaceutical combinations of flurbiprofen, thiocolchicoside, and menthol in the form of topical gels with anti-inflammatory, analgesic, and myorelaxant activities are described.

Abstract: Aspects of the invention relate to compounds, extracts and compositions thereof, and methods of using of the same, to treat neurodegenerative disorders and/or improve brain health. In certain embodiments, said compounds are pomegranate flavonoids.

Abstract: The invention presents nutritional supplements with anti influenza activities. In a preferred embodiment, the invention features administration to a subject an effective dose of a nutritional supplement that includes a combination of all or some of the following ingredients licorice, quercetin, green tea, cinnamon, propolis, and selenium.

Abstract: A topical pharmaceutical formulation made up of nimesulide or a pharmaceutically acceptable derivative of nimesulide, together with thiocolchicoside or a pharmaceutically acceptable derivative of thiocolchicoside. The present invention more particularly relates to pharmaceutical combinations of nimesulide and thiocolchicoside, in the form of topical gels, ointments, cream, sprays, or lotions with anti-inflammatory, analgesic, and myorelaxant activities.

Abstract: Oral pharmaceutical dosage form containing at least two medicaments, in which form the medicaments on the one hand are brought together in a leakproof and in-vivo water soluble wrapping and on the other hand are separated so that the active principle of the combined medicaments cannot come into contact with one another, at least one of the medicaments being selected from the following therapeutic classes: non-steroidal anti-inflammatory drug (NSAID), proton pump inhibitor (PPI), beta-blocker, statin, conversion enzyme inhibitor (CEI), biguanide, myorelaxant, calcium inhibitor, corticoid, antidepressant, benzodiazepine, non-atropine-like intestinal transit retarder, intestinal antibacterial, and the following therapeutic molecules: spironolactone, propranolol, clarithromycin, amoxycillin, low-dose acetylsalicylic acid, potassium, clopidogrel.

Abstract: The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFR1, are disclosed to prevent tumor development in subjects at risk for developing colorectal cancer (CRC). The present invention also relates to methods of identifying increased risk in developing CRC in a subject, including methods of assessing the efficacy of a chemotherapeutic regimen. Further, the present invention relates to methods for identifying anti-neoplastic agents.

Abstract: The present invention relates to a novel assay or screen for identifying compounds with potential therapeutic value for the treatment of protein trafficking diseases such as Cystic Fibrosis (CF) and nephrogenic diabetes insipidus (NDI). The usual approach involves expressing the mutant form of the gene in cells and assaying function in a multiwell format when cells are exposed to libraries of compounds. Although such functional assays are useful, they do not directly test the ability of a compound to correct defective trafficking of the protein. To address this a novel corrector screening assay for CF has been developed in which the appearance of the mutant protein at the cell surface is measured as the assay output. This assay was used to screen more than 3100 compounds. This novel screening approach to protein trafficking diseases is robust and general, and may enable the selection of molecules that can be translated rapidly to a clinical setting.

Abstract: There is provided a medicament capable of enhancing the antimicrobial peptide production ability. The medicament contains, as an active ingredient, a compound which is glycyrrhizin or a pharmaceutically acceptable salt thereof and capable of inhibiting the production of at least one of interleukin-10 (IL-10) and chemokine CCL2. The antimicrobial peptide is preferably defensin or cathelicidin.

Abstract: The present invention relates to synergistic combinations of the compound 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from anthracyclines and topisomerase II inhibitors, which have anti-tumor activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from etoposide, and doxorubicin. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

Abstract: An agent for preventing or ameliorating skin aging, which exhibits a more excellent effect on the suppression of formation, or the amelioration, of wrinkles on the skin or sagging skin. An agent for preventing or ameliorating skin aging, containing triterpenoid saponins represented by the following formula (1) as an active ingredient, wherein at least one of R1 and R2 is a tigloyl group and the other represents a tigloyl group or an angeloyl group; R3 represents a methyl group or a hydroxymethyl group; and R4 represents Glc, Xyl or Gal.